What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Participants will undergo MRI scans without the administration of a contrast agent (unenhanced MRI) and IV-infused MPB-2043 for 1 hour.”In the company’s words, NCT06540443 on ClinicalTrials.gov
- Tested for
- Head and Neck Squamous Cell Carcinoma, Lymph Node Metastasis
- Main trialPhase 1
- “This study evaluates the safety and effectiveness of MPB-2043, a superparamagnetic iron oxide (SPIO) contrast agent, for enhancing MRI in detecting metastatic lymph nodes in head and neck cancer. The study compares four doses of MPB-2043 (0.5 mg/kg, 1 mg/kg, 2 mg/kg, and 3 mg/kg) and assesses the optimal timing for post-dose imaging using T1/T2/T2\*-weighted sequences to improve the accuracy of nodal staging.”In the company’s words, NCT06540443 on ClinicalTrials.gov
Other drugs for Head and Neck Squamous Cell Carcinoma
- APG-157Aveta Biomics, Inc. · Phase 3
- PembrolizumabMerck & Co. · Phase 2/3
- IvonescimabAkeso · Summit Therapeutics · Phase 3
- FiclatuzumabAVEO Pharmaceuticals, Inc. · Phase 3
- SYS6002CSPC · Phase 3
- MRG003Lepu Biopharma Co., Ltd. · Phase 3
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Recruiting | Jun 2026 | Pilot Study of MPB-2043 Enhanced MRI for Nodal Staging in Head and Neck Squamous Cell Carcinomas |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026